December 11, 2017

Selinexor Plus Sorafenib May Benefit Patients with Relapsed/Refractory FLT3-Mutated AML

The combination of selinexor and sorafenib appears to be safe with clinical activity and apoptosis induction in patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia […]
December 5, 2017

New Drug Target Discovered for Acute Myeloid Leukemia

 A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia (AML) cells without harming non-leukemic blood cells 
November 13, 2017

Responses Better With Bosutinib vs Imatinib in Untreated CML

Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the […]
November 9, 2017

Alectinib Approved as First-Line Therapy for ALK-Positive Metastatic NSCLC

Clinicians now have a new first-line therapy that may significantly improve care for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). On […]
September 13, 2017

AML FDA Breaks New Ground With First Approved Gene Therapy For Cancer

When oncologist Dr. Carl June heard the Food and Drug Administration’s decision to bring the first gene therapy to market in the US, he pinched himself, […]
August 18, 2017

FDA Approves New Acute Lymphoblastic Leukemia Treatment

The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in […]
July 6, 2017

Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to […]
June 28, 2017

Experimental FLT3 Inhibitor May Benefit Patients with Refractory AML

Clinicians may soon have a new tool to aid patients with refractory acute myeloid leukemia (AML). Researchers at the Perelman School of Medicine at the University […]
June 20, 2016

ASCO 2016

The American Society of Clinical Oncology’s annual meeting, one of the most important cancer conferences of the year, concluded June 7th. This year’s theme was ‘collective […]
February 5, 2016

ASH 2015

The American Society of Hematology (ASH), the premier event for scientific exchange in the field of hematology, recently concluded its annual meeting in Orlando, Florida. Oral […]
July 7, 2015

News From ASCO 2015

The annual American Society of Clinical Oncology (ASCO) meeting was held last week in Chicago, bringing together thousands of oncology professionals from around the world to […]
February 19, 2015

TKI Famitinib Delays Progression in Advanced Colorectal Cancer

The tyrosine kinase inhibitor famitinib was associated with a significant improvement in progression-free survival among patients with advanced or metastatic colorectal cancer, according to the results […]
February 19, 2015

Baseline AFP Protein Levels Affect Ramucirumab Benefit in HCC

Patients with hepatocellular carcinoma (HCC) may derive greater benefit from treatment with second-line ramucirumab if their baseline alpha-fetoprotein (AFP) levels are greater than 400 ng/mL, according […]
February 19, 2015

Surgery may not be necessary for all rectal cancer patients;

Patients with rectal cancer who completed neoadjuvant therapy with a clinical complete response but did not undergo rectal resection had similar 4-year survival rates as patients […]
February 19, 2015

Vitamin D Levels Linked to Colorectal Cancer Survival

Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with a combination of chemotherapy and targeted therapy. The results […]
February 19, 2015

NAPOLI-1: MM-398 Combo Shows Benefit in Metastatic Pancreatic Cancer

The addition of the novel agent MM-398 to second-line 5-FU/leucovorin extended survival in patients with metastatic pancreatic cancer, according to an expanded analysis of the phase […]
February 19, 2015

Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival.

Twice as many patients with metastatic colorectal cancer remained alive after 5 years with a four-drug chemotherapy regimen plus bevacizumab (Avastin) versus three drugs and the […]
February 19, 2015

The 2015 ASCO Gastrointestinal Cancers Symposium

The 2015 ASCO Gastrointestinal Cancers Symposium, held last month in San Francisco, brought together oncology professionals to highlight the latest research and science in cancers of […]
December 12, 2014

Investigational Antibody Demonstrates Efficacy, Safety for Patients with Aggressive Multiple Myeloma in Phase I Study

SAR650984 (SAR) is another anti-CD38 antibody that has shown single-agent activity in Phase I testing among heavily pre-treated myeloma patients. In this Phase Ib trial, researchers […]
December 12, 2014

Carfilzomib Represents Potent, Effective Addition to Standard Multiple Myeloma Therapy in Phase III Study

The recently approved targeted treatment carfilzomib has been shown to help slow or halt the spread of cancer by targeting the mechanisms that control excess proteins […]
December 12, 2014

Brentuximab Vedotin Prolongs Post-Transplant Survival in Hard-to-Treat Lymphoma Patients in 
Phase III Study

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous […]
December 12, 2014

Advances in Lymphoma and Multiple Myeloma Treatment Seek to Improve Outcomes for Patients with Hard-To-Treat Disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented at […]
December 12, 2014

Novel Strategies Direct Immune System to Attack Recurrent, Hard-To-Treat Blood Cancers

Novel treatments that harness the body’s own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, […]
December 12, 2014

Targeted Therapy Effective in Elderly Patients with Philadelphia-Positive Acute Lymphocytic Leukemia

While rates of remission among elderly patients with leukemia continue to improve, the outlook remains poor among those with a disease subtype present in nearly one-third […]
December 12, 2014

Novel Combinations of New and Existing Therapies Yield Promising Results for Leukemia Patients with poor Prognoses

Recognizing that leukemia cannot be conquered with a “one-size-fits-all” approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for […]
December 12, 2014

News From ASH

The American Society of Hematology (ASH) is the world’s largest professional society of hematologists dedicated to furthering the understanding, treatment, and prevention of disorders affecting the […]
October 7, 2014

Newly Approved Drugs

Cancer researchers have been almost giddy in the last couple of years about the potential of drugs like Keytruda, which seem to solve a century-old mystery […]
October 7, 2014

Newly Approved Drugs

Could you discuss the KEYNOTE study results and the approval of pembrolizumab? Pembrolizumab was approved because it is active for the treatment of metastatic melanoma and […]
September 26, 2014

Newly Approved Drugs

Last week, the FDA approved pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma following progression on prior therapies. In the pivotal KEYNOTE-001 […]
August 15, 2014

MHOA Monthly Newsletter

MHOA Monthly Newsletter No.1 Positivity in Adversity “Strength does not come from physical capacity. It comes from indomitable will.” -Mahatma Ghandi
August 1, 2014

MHOA Research and Clinical Trials

[mc_carousel id=”carousel” carousel_images=”2770,2771,2772,2750,2773″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] Thank You For Your Interest In Clinical Trials at MHOA Currently Enrolling […]
August 1, 2014

Featured Physicians and Caregivers

“I love the fact that today, with all the advances in diagnostics, drugs, and personalized cancer treatments, working with cancer patients is an exciting and optimistic […]
August 1, 2014

New Cancer Treatments

Brain Cancer New tumor-targeting agents (APC) able to seek out and find solid tumors, even illuminating brain cancer stem cells that resist current treatments Science Daily […]